Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies
CORRECTING and REPLACING The Vatican Hosts Third International Regenerative Medicine Conference
GlaxoSmithKline Start Second Phase Study of Antibody For Inflammatory Osteoarthritis
This ETF holds a swath of large- and mid-cap U.S. healthcare companies.
Five frequently asked questions for shell-shocked fund investors.
GlaxoSmithKline GSK reported solid second-quarter results on Wednesday that were largely in line with our expectations, and we don't anticipate any changes to our fair value estimate. Sales increased 10% from the prior year driven by strong sales of asthma medicine Advair, diabetes medicine ...
Worry less about beating the benchmark and more about dividend growth and achieving your desired outcomes, says Morningstar's Josh Peters.
Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.
The U.K. will remain a good hunting ground for dividend-paying stocks even if Scotland decides to become independent, says Morningstar's Josh Peters.